M. Medvedec

发表

A New Age for Recombinant Human Thyroid-Stimulating Hormone?

M. Medvedec, 2009, Journal of Nuclear Medicine.

Thyroid stunning in vivo and in vitro

M. Medvedec, 2005, Nuclear medicine communications.

Tc-99m DTPA renal scintigraphy using deconvolution analysis with six functional images of the mean time to evaluate acute pyelonephritis.

D. Huić, D. Batinic, K. Vrljicak, 1999, Clinical Nuclear Medicine.

Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.

M. Žuvić, D. Huić, D. Ivancevic, 1996, Nuclear medicine communications.

Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine

Sanja Kusačić Kuna, Marija Despot, T. Samardžič, 2009, Nuclear medicine communications.

Clinical Engineering and Clinical Dosimetry in Patients with Differentiated Thyroid Cancer Undergoing Thyroid Remnant Ablation with Radioiodine-131

D. Dodig, M. Medvedec, 2010 .

Determination of small objects from pinhole scintigrams.

T. Šmuc, M. Žuvić, S. Loncaric, 1998, Nuclear medicine communications.

Has come the day to do away with thyroid remnant ablation targeting 300 gray (Gy)

D. Dodig, M. Medvedec, 2007 .

Do we read carefully?

M. Medvedec, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Seeking a radiobiological explanation for thyroid stunning

M. Medvedec, 2001, European Journal of Nuclear Medicine.

Thyroid 'stunning': full-quantitative explanation based on radiation absorbed dose analysis

S. Loncaric, D. Grošev, D. Dodig, 2000 .

As soon as possible is already to late

S. Loncaric, D. Grošev, M. Medvedec, 2001 .

Improved planning of radioiodine therapy for thyroid cancer.

M. Medvedec, 2002, Journal of Nuclear Medicine.